knowledge -WSS

knowledge

author：explore 2025-10-01 12:36:04 - browse：8

Humana sign -- health business coverage from STAT — Humana’s Medicare Advantage business is faring even worse than the company let on last week. Ed Reinke/AP

Humana’s Medicare Advantage business is faring even worse than the company let on last week, with “unprecedented” numbers of older adults getting medical care and busting through its tactics for holding up payment.

The country’s second largest private Medicare insurer disclosed Thursday it’s projecting roughly half the profit in 2024 that investors had expected. The news comes a week after Humana already lowered its projected 2023 profit, which still came in at north of $3 billion before taxes.

The stock market’s punishment was swift and decisive, sinking Humana’s share price by roughly 12% at midday. Outgoing CEO Bruce Broussard worked to calm nerves on the company’s investor call, reiterating his confidence in MA. Humana went all-in on the program when it announced last year it would wind down its employer business, but that comes as regulators are beefing up scrutiny of MA plans.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Lawmakers grill UnitedHealth CEO on Change cyberattack

WSS

Has Bernie Sanders reached the limit of his pharma bullying effort?

How to keep neuroscience’s past racism from being its future

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Is it ever OK for doctors to lie to their patients?

Medicare Advantage beneficiaries sue Humana over algorithm use

HHS's proposed rule does nothing to address the climate crisis

entertainment

knowledge

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Grail spinoff by Illumina should end disastrous merger attempt

Hepatitis C has a cure — but many Americans still lack access to it

Hospitals owned by private equity see complications spike 25%

Psychedelics group wrestles with new pharma identity

Sepsis can kill a child within hours. Here's how hospitals are fighting back

The high cost of giving birth even with insurance

Christmas in the PICU brings some surprising joy

hotspot

AltruBio raises $225 million to develop ulcerative colitis drug

Grail spinoff by Illumina should end disastrous merger attempt

Lawmakers grill UnitedHealth CEO on Change cyberattack

PBM executives asked to testify by House panel

David Ricks of Eli Lilly: best biopharma CEO of 2023

Can gargling with Listerine treat gonorrhea of the mouth?

knowledge

knowledge

focus

hotspot